Klinisk och translationell bröstcancerforskning – Alexios Matikas team

Publikationer

Alla gruppmedlemmars publikationer

• Article: EUROPEAN JOURNAL OF CANCER. 2026;239:116699

  Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis

  Filis P; Markozannes G; Salgkamis D; Tsiknakis N; Zerdes I; Pagkalidou E; Manou M; Filis N; Papakonstantinou A; Mavroudis D; Matikas A; Tsilidis KK; Foukakis T
• Review: JOURNAL OF INTERNAL MEDICINE. 2026;299(5):538-569

  Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field

  Bjorkstrom K; Matikas A; Svedman FC; Bjorgvinsson E; Zupancic M; Villabona L; Eriksson H; Skribek M; Fernebro J; Lindskog M; Frodin J-E; Ullen A; Ekman S; Helgadottir H
• Journal article: ESMO OPEN. 2026;11(5):107696

  Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.

  Filis P; Liu X; Matikas A; Untch M; Steger GG; Johansson H; Hellström M; Gnant M; Loibl S; Brandberg Y; Bergh J; Foukakis T
• Article: NATURE COMMUNICATIONS. 2026;17(1):3403

  Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2-breast cancer: a randomized phase II trial

  Matikas A; Tzoras E; Sarafidis M; Sifakis EG; Bjohle J; Barnekow E; Margolin S; Isaksson-Friman E; Kessler LE; Zouzos A; Johansson H; Hellstrom M; Agartz S; Gryback P; Salgkamis D; Zerdes I; Wang K; Hartman J; Acs B; Sun W; Boyaci C; Villacampa G; Pascual T; Gavila J; Prat A; Perou C; Brandberg Y; Bergh J; Hatschek T; Foukakis T
• Article: RADIOTHERAPY AND ONCOLOGY. 2026;219:111523

  Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study

  Becherini C; Blondeaux E; Delucchi V; Visani L; Kim HJ; Coussy F; Bernstein-Molho R; Di Meglio A; Hilbers FS; Pogoda K; Kwong A; Agostinetto E; Baten A; Bajpai J; Balmana J; Moore HCF; Partridge AH; Rousset-Jablonski C; Phillips K-A; Toss A; Renaud T; Ferrari A; Peccatori FA; Sanchez L; Paluch-Shimon S; Cui W; Wong SM; Ryu JM; Fruscio R; Lee MK; Vernieri C; Matikas A; Couch FJ; De Marchis L; Dieci MV; Aguilar-Y-Mendez D; Hwang SE; Rozenblit M; Guven DC; Mrinakova B; Harbeck N; Sanchez-Bayona R; Boni L; Lambertini M; Meattini I
• Journal article: CANCER RESEARCH. 2026;86(7):3527

  Clonal evolutionary trajectory of HER2-positive breast cancer with ERBB2 or PIK3CA mutations under neoadjuvant treatment

  Wang K; Zerdes I; Sifakis EG; Salgkamis D; Bergh J; Hatschek T; Matikas A; Foukakis T
• Article: ANNALS OF ONCOLOGY. 2026;37(3):364-377

  Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study

  Toss A; Blondeaux E; Tenedini E; Bonamici L; Graffeo R; Livraghi L; Villarreal-Garza C; Molho RB; Kwong A; Balmana J; Wildiers H; Agostinetto E; Phillips KA; Pogoda K; Renaud T; Rousset-Jablonski C; Ferrari A; Moore HCF; Peccatori FA; Paluch-Shimon S; Fruscio R; Micheri C; Wong SM; Cui W; Vernieri C; Lee MK; De Marchis L; Couch FJ; Del Mastro L; Puglisi F; Meireles PA; Kemp Z; Matikas A; Plichta J; Del Pilar Estevez-Diz M; Di Meglio A; Cichowska-Cwalinska N; Gianni C; Yerushalmi R; Sanchez-Bayona R; Mrinakova B; Matos L; Bianchini G; Caleffi M; Krivokuca A; Abdou Y; Marino-Marino M; Parokonnaya A; Okano M; Antone N; Saavedra C; Sonnenblick A; Duchnowska R; Pais HL; Harbeck N; Cortesi L; Delucchi V; De Angelis C; Lambertini M
• Journal article: CLINICAL CANCER RESEARCH. 2026;32(4_Supplement):ps4-12-24-ps4-12-24

  Abstract PS4-12-24: Risk and Pattern of Relapse in Triple-Negative Breast Cancer with Pathological Complete Response after Neoadjuvant Treatment: Updated Results from the European GAMBIT Real-world Study

  Dieci M; Foukakis T; Giacchetti S; Desmedt C; Frenel J; Gasparini E; Kok M; Vigneri P; Jacot W; Vernieri C; Lambertini M; Patanè F; Piacentini F; Bria E; Zambelli A; Trapani D; Botticelli A; Garrone O; Massa D; Lando S; Matikas A; Someil L; Floris G; Campone M; Ragazzi M; Lips E; Martorana F; Bonomi G; Papakostantinou A; Nicolé L; Zerdes I; Neven P; Rotolo M; Horlings H; Nucera S; Gudin de Vallerin A; Vingiani A; Tos AD; Guarneri V
• Journal article: CLINICAL CANCER RESEARCH. 2026;32(4_Supplement):pd4-07-pd4-07

  Abstract PD4-07: Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study

  Blondeaux E; Meacci A; Gil MF; Klocker E; Coussy F; Kim H; Molho RB; Hilbers F; Di Meglio A; Kwong A; Pogoda K; Bajpai J; Wildiers H; Agostinetto E; Balmana J; Moore HC; Phillips K; Partridge AH; Rousset-Jablonski C; Peccatori FA; Toss A; Renaud T; Anghelone C; Cruz AB; Paluch-Shimon S; Lee J; Fruscio R; Cui W; Wong SM; Lee M; Rozenblit M; Vernieri C; Villarreal-Garza C; Matikas A; Dieci M; De Marchis L; Plichta JK; Ruddy KJ; Guven DC; Puglisi F; Kemp Z; Meireles PA; Del Mastro L; Delucchi V; Lambertini M
• Journal article: CLINICAL CANCER RESEARCH. 2026;32(4_Supplement):pd12-01-pd12-01

  Abstract PD12-01: Surgical management of young BRCA1/2 carriers with early onset breast cancer

  Wong SM; Blondeaux E; Delucchi V; Coussy F; Molho RB; Linn S; Di Meglio A; Kwong A; Pogoda K; Agostinetto E; Nevelsteen I; Balmana J; Moore HC; Toss A; Ferrari A; Rousset-Jablonski C; Renaud T; Phillips K; PeccatorI FA; Ipina MA; Paluch-Shimon S; Ryu J; Kui W; Lee M; Fruscio R; Rozenblit M; Vernieri C; Matikas A; Dieci M; Couch FJ; De Marchis L; Hwang SE; Mendez DA-Y; Guven DC; Swain M; Gianni C; Spinaci S; Montagna G; Lambertini M; Kim H
• Journal article: CLINICAL CANCER RESEARCH. 2026;32(4_Supplement):ps2-08-01-ps2-08-01

  Abstract PS2-08-01: A predictive gene signature for benefit from dose-dense adjuvant chemotherapy in patients with high-risk early breast cancer: results from the PANTHER phase III trial

  Salgkamis D; Sarafidis M; Sifakis E; Zerdes I; Agartz S; Hartman J; Hellström M; Foukakis T; Bergh J; Matikas A
• Conference publication: CLINICAL CANCER RESEARCH. 2026;32

  Risk and Pattern of Relapse in Triple-Negative Breast Cancer with Pathological Complete Response after Neoadjuvant Treatment: Updated Results from the European GAMBIT Real-world Study

  Dieci M; Foukakis T; Giacchetti S; Desmedt C; Frenel J; Gasparini E; Kok M; Vigneri P; Jacot W; Vernieri C; Lambertini M; Patane F; Piacentini F; Bria E; Zambelli A; Trapani D; Botticelli A; Garrone O; Massa D; Lando S; Matikas A; Someil L; Floris G; Campone M; Ragazzi M; Lips E; Martorana F; Bonomi G; Papakostantinou A; Nicole L; Zerdes I; Neven P; Rotolo M; Horlings H; Nucera S; de Vallerin AG; Vingiani A; Tos AD; Guarneri V
• Conference publication: CLINICAL CANCER RESEARCH. 2026;32

  Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study

  Blondeaux E; Meacci A; Gil MF; Klocker E; Coussy F; Kim H; Molho RB; Hilbers F; Di Meglio A; Kwong A; Pogoda K; Bajpai J; Wildiers H; Agostinetto E; Balmana J; Moore HC; Phillips K; Partridge AH; Rousset-Jablonski C; Peccatori FA; Toss A; Renaud T; Anghelone C; Cruz AB; Paluch-Shimon S; Lee J; Fruscio R; Cui W; Wong SM; Lee M; Rozenblit M; Vernieri C; Villarreal-Garza C; Matikas A; Dieci M; De Marchis L; Plichta JK; Ruddy KJ; Guven DC; Puglisi F; Kemp Z; Meireles PA; Del Mastro L; Delucchi V; Lambertini M
• Conference publication: CLINICAL CANCER RESEARCH. 2026;32

  Surgical management of young BRCA1/2 carriers with early onset breast cancer

  Wong SM; Blondeaux E; Delucchi V; Coussy F; Molho RB; Linn S; Di Meglio A; Kwong A; Pogoda K; Agostinetto E; Nevelsteen I; Balmana J; Moore HC; Toss A; Ferrari A; Rousset-Jablonski C; Renaud T; Phillips K; Peccator FAI; Ipina MA; Paluch-Shimon S; Ryu J; Kui W; Lee M; Fruscio R; Rozenblit M; Vernieri C; Matikas A; Dieci M; Couch FJ; De Marchis L; Hwang SE; Aguilar-y Mendez D; Guven DC; Swain M; Gianni C; Spinaci S; Montagna G; Lambertini M; Kim H
• Conference publication: CLINICAL CANCER RESEARCH. 2026;32

  A predictive gene signature for benefit from dose-dense adjuvant chemotherapy in patients with high-risk early breast cancer: results from the PANTHER phase III trial

  Salgkamis D; Sarafidis M; Sifakis E; Zerdes I; Agartz S; Hartman J; Hellstrom M; Foukakis T; Bergh J; Matikas A
• Article: ESMO OPEN. 2026;11(2):106062

  Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials

  Filis P; Filis N; Foukakis T; Matikas A
• Article: CANCER MEDICINE. 2026;15(2):e71570

  Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort Study

  Bergman M; Schiza A; Boyaci C; Acs B; Matikas A; Hartman J; Valachis A
• Review: CANCER TREATMENT REVIEWS. 2026;142:103063

  Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

  Escudero A; Bellet M; Saura C; Aguilera A; Papakonstantinou A; Tolosa P; Garcia-Saenz JA; Moreno F; Sa ALD; Schettini F; Segui E; Gonzalez-Rodriguez M; Navarro V; Ferrero-Cafiero JM; Gonzalez X; Hernando C; Matikas A; Prat A; Oliveira M; Pascual T; Villacampa G
• Article: BREAST CANCER RESEARCH. 2025;28(1):19

  Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes

  Castresana-Aguirre M; Matikas A; Lindstrom LS; Tobin NP
• Article: LANCET REGIONAL HEALTH-EUROPE. 2025;59:101471

  Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

  Liu X; Binicy B; Acs B; Bergman LE; Loibl S; Gnant M; Untch M; Valachis A; Bergh J; Hartman J; Foukakis T; Matikas A
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2025

  Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Article: LANCET REGIONAL HEALTH-EUROPE. 2025;58:101432

  Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study

  Toli MA; Liu X; Massa D; Lando S; Boman C; Tsiknakis N; Tranchell C; Papakonstantinou A; Fotia G; Vernieri C; Guarneri V; Bergh J; Dieci MV; Bergman LE; Matikas A; Foukakis T
• Dataset: KI DATA REPOSITORY. 2025

  Data for: Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER+/HER2- breast cancer: a randomized phase II trial

  Matikas A; Sarafidis M; Hatschek T; Foukakis T
• Article: ECLINICALMEDICINE. 2025;88:103493

  Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study

  Bergman LE; Matikas A; Liu X; Foukakis T
• Doctoral thesis: 2025

  Breast cancer biomarkers : dynamics during treatment and metastatic progression

  Boman C
• Journal article: ANNALS OF ONCOLOGY. 2025;36:s453-S428

  Clinical course and molecular characteristics of oligometastatic breast cancer: Results from two randomized neoadjuvant trials

  Matikas A; Sarafidis M; Wang K; Tzoras E; Sifakis EG; Zerdes I; Bergh J; Hatschek T; Foukakis T
• Conference publication: ANNALS OF ONCOLOGY. 2025;36:s1033-s1034

  Liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis

  Filis P; Pagkalidou E; Tsiknakis N; Salgkamis D; Zerdes I; Markozannes G; Manou M; Papakonstantinou A; Tsilidis K; Matikas A; Foukakis T
• Study protocol: BMJ OPEN. 2025;15(8):e102626

  Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

  Matikas A; Naume B; Wildiers H; Sonke G; Dieci MV; Karakatsanis A; Andersson A; Barnekow E; Kessler LE; Einbeigi Z; Killander F; Linderholm B; Schiza A; Valachis A; Nearchou A; Engebraaten O; Porojnicu A; Soland MH; Mannsaker B; Raj SX; Blix ES; Nordstrand CS; Lambertini M; Vernieri C; Punie K; Sotiriou C; Bergh J; Villacampa G; Zouzos A; Hellstrom M; Hartman J; Foukakis T
• Article: BREAST. 2025;82:104489

  Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study

  Kjallquist U; Tsiknakis N; Acs B; Margolin S; Kessler LE; Levy S; Ekholm M; Lundgren C; Olsson E; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
• Journal article: CLINICAL CANCER RESEARCH. 2025;31(12_Supplement):p4-01-30-p4-01-30

  Abstract P4-01-30: Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment

  Wang K; Gaessler LF; Zerdes I; Zhu Y; Sifakis E; Salgkamis D; Harbers L; Crosetto N; Bergh J; Hatschek T; Johansson HJ; Matikas A; Lehtiö J; Foukakis T
• Journal article: CLINICAL CANCER RESEARCH. 2025;31(12):p2-01-30-p2-01-30-P20130

  Gene Expression patterns in early ER+/HER2-breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial

  Tzoras E; Sarafidis M; Sifakis EG; Salgkamis D; Acs B; Sun W; Zerdes I; Wang K; Bergh J; Hatschek T; Matikas A; Foukakis T
• Journal article: CLINICAL CANCER RESEARCH. 2025;31(12):p1-02-28-p1-02-28

  PDGFRa plus /FAP- fibroblasts at multiplex in situ resolution are associated with resistance to HER2 blockade in neoadjuvant treated HER2+breast cancer: results from the Swedish PREDIX HER2 trial

  Manikis G; Tzoras E; Tsiknakis N; Bernabe AM; Zhu Y; Wang K; Zerdes I; Bergh J; Hatschek T; Ostman A; Matikas A; Foukakis T
• Conference publication: CLINICAL CANCER RESEARCH. 2025;31(12):gs1-08-gs1-08

  Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study

  Lambertini M; Sonnenblick A; Agostinetto E; Bas R; Kim HJ; Franzoi MA; Molho RB; Linn S; Kwong A; Pogoda K; Balmana J; Smeets A; Bajpai J; Moore HCF; Partridge AH; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Mando P; Lee JE; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Guven DC; Lee M; Villarreal-Garza C; Hwang SE; De Marchis L; Puglisi F; Kemp Z; Meireles PA; Parokonnaya A; Werutsky G; Okano M; Azim Jr HA; Mati K; Rosenberg S; Gelber R; Boni L; Blondeaux E
• Meeting abstract: CLINICAL CANCER RESEARCH. 2025;31(12):p2-05-30-p2-05-30-P20530

  Ki-67 dynamics during neoadjuvant treatment of breast cancer and their added prognostic value to the Neo-Bioscore model: a population-based cohort study

  Toli MA; Bergman LE; Liu X; Boman C; Tranchell C; Bergh J; Matikas A; Foukakis T
• Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2025;43(16_SUPPL):tps631

  A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).

  Matikas A; Naume B; Wildiers H; Dieci MV; Sonke GS; Karakatsanis A; Schiza A; Punie K; Sotiriou C; Lambertini M; Vernieri C; Villacampa G; Hellstrom M; Bergh JCS; Hartman J; Foukakis T
• Conference publication: CLINICAL CANCER RESEARCH. 2025;31(12)

  Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment

  Wang K; Gaessler LF; Zerdes I; Zhu Y; Sifakis E; Salgkamis D; Harbers L; Crosetto N; Bergh J; Hatschek T; Johansson HJ; Matikas A; Lehtioe J; Foukakis T
• Editorial: ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY. 2025;8:100128

  Bridging the gap: overcoming barriers to implementing gene expression profiling in clinical practice

  Valachis A; Matikas A
• Article: LANCET ONCOLOGY. 2025;26(6):759-770

  Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

  Blondeaux E; Sonnenblick A; Agostinetto E; Bas R; Kim HJ; Franzoi MA; Bernstein-Molho R; Linn S; Kwong A; Pogoda K; Balmana J; Smeets A; Bajpai J; Moore HCF; Partridge AH; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Mando P; Lee JE; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Guven DC; Lee M; Villarreal-Garza C; Hwang SE; De Marchis L; Puglisi F; Kemp Z; Meireles PA; Parokonnaya A; Werutsky G; Okano M; Azim Jr HA; Mati K; Rosenberg S; Gelber R; Boni L; Lambertini M
• Article: JOURNAL OF CLINICAL ONCOLOGY. 2025;43(14):1706-1719

  Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status

  Lambertini M; Blondeaux E; Tomasello LM; Agostinetto E; Hamy A-S; Kim HJ; Franzoi MA; Bernstein-Molho R; Hilbers F; Pogoda K; Wildiers H; Bajpai J; Ignatiadis M; Moore HCF; Partridge AH; Phillips K-A; Toss A; Rousset-Jablonski C; Criscitiello C; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Puglisi F; Rodriguez-Wallberg KA; Duhoux FP; Livraghi L; Bruzzone M; Boni L; Balmana J
• Journal article: ESMO OPEN. 2025;10:104584

  30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy

  Zerdes I; Wang K; Manikis G; Salgkamis D; Zhu Y; Tzoras E; Mezheyeuski A; Acs B; Sifakis EG; Hartman J; Papakonstantinou A; Matikas A; Bergh J; Hatschek T; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104559

  4MO Development and validation of CDKPredX, a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2- breast cancer: Correlative analysis of the randomized phase II PREDIX luminal B trial

  Foukakis T; Tzoras E; Sarafidis M; Sifakis EG; Salgkamis D; Zerdes I; Wang K; Pascual T; Gavilá-Gregori J; Villacampa G; Prat A; Perou CM; Bergh J; Hatschek T; Matikas A
• Journal article: ESMO OPEN. 2025;10:104632

  78P Validation of an AI-based solution for breast cancer risk stratification using digital H&E images: Subgroup analysis within PANTHER clinical trial

  Tzoras E; Salgkamis D; Tsiknakis N; Johansson H; Sun W; Hellström M; Andersson A; Loibl S; Untch M; Denkert C; Jank P; Rantalainen M; Hartman J; Zerdes I; Matikas A; Bergh J; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104589

  35P Deep learning for overall survival risk prediction in early breast cancer using H&E-stained images and clinicopathological variables

  Tsiknakis N; Salgkamis D; Tzoras E; Manikis G; Liu X; Marias K; Acs B; Hartman J; Hellström M; Johansson H; Andersson A; Loibl S; Untch M; Denkert C; Jank P; Zerdes I; Matikas A; Bergh J; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104770

  216P Characteristics and prognosis of NATALEE- and monarchE-eligible early breast cancer populations: Analysis of a Swedish nationwide cohort

  Liu X; Khalilzadeh-Binicy B; Acs B; Bergh J; Hartman J; Foukakis T; Matikas A
• Journal article: ESMO OPEN. 2025;10:104574

  20P Evolution of early-stage ERBB2-mutant, HER2+ breast cancer under neoadjuvant therapy

  Wang K; Zerdes I; Sifakis EG; Salgkamis D; Bergh J; Hatschek T; Matikas A; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104631

  77P The landscape of somatic mutations in high-risk early ER+/HER2- breast cancer patients: Analysis of the randomized phase II PREDIX luminal B trial

  Sarafidis M; Tzoras E; Sifakis EG; Wang K; Salgkamis D; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104627

  73P Prognostic value of the relative change of Ki-67 during neoadjuvant chemotherapy for triple-negative breast cancer: A population-based study

  Toli MA; Liu X; Bergman LE; Lando S; Massa D; Boman CE; Tranchell C; Fotia G; Vernieri C; Guarneri V; Bergh J; Dieci MV; Matikas A; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104761

  207P Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: A population-based study

  Bergman LE; Matikas A; Liu X; Foukakis T
• Journal article: ESMO OPEN. 2025;10:104609

  55P Single-nucleotide polymorphisms associated with haematological toxicities during adjuvant chemotherapy in high-risk early breast cancer patients: Results from the PANTHER phase III trial

  Salgkamis D; Liu X; Rivera N; Papakonstantinou A; Hellström M; Agartz S; Sifakis EG; Zerdes I; Bergh J; Matikas A; Foukakis T
• Article: INTERNATIONAL JOURNAL OF CANCER. 2025;156(8):1621-1633

  Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer

  Kouvaraki M; Zerdes I; Sifakis EG; Sarafidis M; Matikas A; Tzoras E; Kjallquist U; Stathopoulou K; Lovrot J; Alkodsi A; Hartman J; Sotiriou C; Richard F; Hatschek T; Herold N; Bergh J; Rassidakis GZ; Foukakis T
• Article: JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. 2025;23(4):e247093

  Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study

  Boman C; Tranchell C; Liu X; Bergman LE; Toli MA; Bergh J; Foukakis T; Matikas A
• Preprint: BIORXIV. 2025

  Decoding Cell Cycle Phase Variations in Cancer Hallmarks Across Breast Cancer Subgroups

  Castresana-Aguirre M; Matikas A; Lindström LS; Tobin NP
• Article: NPJ BREAST CANCER. 2025;11(1):23

  Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial

  Zerdes I; Matikas A; Mezheyeuski A; Manikis G; Acs B; Johansson H; Boyaci C; Boman C; Poncet C; Ignatiadis M; Bai Y; Rimm DL; Cameron D; Bonnefoi H; Bergh J; Macgrogan G; Foukakis T
• Article: ECLINICALMEDICINE. 2025;81:103116

  Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis

  Papakonstantinou A; Villacampa G; Navarro V; Oliveira M; Valachis A; Pascual T; Matikas A
• Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2025;207:104602

  Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations

  Filis P; Markozannes G; Chan DSM; Mauri D; Foukakis T; Matikas A; Droufakou S; Pentheroudakis G; Tsilidis K
• Article: EJSO. 2025;51(3):109587

  Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study

  Liu X; Bergman LE; Boman C; Foukakis T; Matikas A
• Article: LANCET REGIONAL HEALTH-EUROPE. 2025;49:101162

  Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial

  Matikas A; Papakonstantinou A; Loibl S; Steger GG; Untch M; Johansson H; Tsiknakis N; Hellstrom M; Greil R; Moebus V; Gnant M; Bergh J; Foukakis T
• Review: DRUG DISCOVERY TODAY. 2025;30(1):104250

  Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236

  Filis P; Salgkamis D; Matikas A; Zerdes I
• Article: ESMO OPEN. 2024;9(10):103714

  Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

  Agostinetto E; Bruzzone M; Hamy A-S; Kim HJ; Chiodi C; Bernstein-Molho R; Linn S; Pogoda K; Carrasco E; Derouane F; Bajpai J; Nader-Marta G; Lopetegui-Lia N; Partridge AH; Cortesi L; Rousset-Jablonski C; Giugliano F; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Aguilar Y Mendez D; De Marchis L; Borea R; Puglisi F; Pistelli M; Kufel-Grabowska J; Di Rocco R; Mariamidze E; Atzori F; Kourie HR; Popovic L; de Azambuja E; Blondeaux E; Lambertini M
• Article: JAMA ONCOLOGY. 2024;10(10):1331-1341

  Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer

  Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martinez-Saez O; Sanchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
• Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(26):3077-3082

  Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

  Matikas A; Moebus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstroem P; Schmatloch S; Johansson H; Hellstroem M; Brandberg Y; Gnant M; Loibl S; Foukakis T; Bergh J
• Article: BRITISH JOURNAL OF CANCER. 2024;131(4):718-728

  A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression

  Boman C; Liu X; Eriksson Bergman L; Sun W; Tranchell C; Toli MA; Acs B; Bergh J; Foukakis T; Matikas A
• Journal article: ANNALS OF ONCOLOGY. 2024;35:s356

  A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)

  Foukakis T; Naume B; Karakatsanis A; Andersson A; Barnekow E; Kessler LE; Einbeigi Z; Engebraten O; Killander F; Linderholm BK; Schiza A; Valachis A; Bergh J; Villacampa G; Zouzos A; Hellstrom M; Hartman J; Matikas A
• Conference publication: ANNALS OF ONCOLOGY. 2024;35:s1112

  Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations

  Filis P; Markozannes G; Chan D; Mauri D; Foukakis T; Matikas A; Droufakou S; Pentheroudakis G; Tsilidis K
• Article: IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS. 2024;28(9):5312-5322

  Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images

  Tsiknakis N; Manikis G; Tzoras E; Salgkamis D; Vidal JM; Wang K; Zaridis D; Sifakis E; Zerdes I; Bergh J; Hartman J; Acs B; Marias K; Foukakis T
• Article: ANNALS OF ONCOLOGY. 2024;35(9):792-804

  Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

  Arecco L; Bruzzone M; Bas R; Kim HJ; Di Meglio A; Bernstein-Molho R; Hilbers FS; Pogoda K; Carrasco E; Punie K; Bajpai J; Agostinetto E; Lopetegui-Lia N; Partridge AH; Phillips KA; Toss A; Rousset-Jablonski C; Curigliano G; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Couch FJ; Dieci MV; Matikas A; Rozenblit M; Mendez DA-Y; De Marchis L; Puglisi F; Fabi A; Graff SL; Witzel I; Hernandez AR; Fontana A; Pesce R; Duchnowska R; Pais HL; Sini V; Sokolovic E; de Azambuja E; Ceppi M; Blondeauxt E; Lambertini M
• Article: CANCER. 2024;130(16):2746-2762

  Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

  Schettini F; Blondeaux E; Molinelli C; Bas R; Kim HJ; Di Meglio A; Bernstein Molho R; Linn SC; Pogoda K; Carrasco E; Punie K; Agostinetto E; Lopetegui-Lia N; Phillips K-A; Toss A; Rousset-Jablonski C; Acheritogaray M; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Puglisi F; Vasconcelos de Matos L; Marino M; Teixeira L; Graffeo R; Rognone A; Chirco A; Antone N; Abdou Y; Marhold M; Bozovic-Spasojevic I; Cortes Salgado A; Carmisciano L; Bruzzone M; Curigliano G; Prat A; Lambertini M
• Article: SCIENTIFIC REPORTS. 2024;14(1):18275

  Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue

  Salgkamis D; Sifakis EG; Agartz S; Wirta V; Hartman J; Bergh J; Foukakis T; Matikas A; Zerdes I
• Editorial: OBSTETRICAL & GYNECOLOGICAL SURVEY. 2024;79(8):446-449

  Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Editoral Comment

  Lambertini M; Blondeaux E; Agostinetto E; Hamy A-S; Kim HJ; Di Meglio A; Molho RB; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; de Marchis L; del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; de Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; de Giorgi U; Sonnenblick A; Chiodi C; Lee Y-J; Maria C; Azim Jr HA; Boni L; Partridge AH
• Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2024;2024:1-5

  Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast Histopathology.

  Tsiknakis N; Wang K; Salgkamis D; Tzoras E; Manikis GC; Sifakis E; Bergh J; Zerdes I; Marias K; Matikas A; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)

  Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial

  Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
• Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16_suppl):521

  Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.

  Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
• Article: NATURE COMMUNICATIONS. 2024;15(1):3837

  Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer

  Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
• Conference publication: ESMO OPEN. 2024;9:103031

  23P Longitudinal evaluation of PAM50 molecular subtypes in patients receiving neoadjuvant HER2-targeted therapy in the PREDIX HER2 trial

  Zhu Y; Sifakis EG; Wang K; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
• Conference publication: ESMO OPEN. 2024;9:103110

  122P Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer

  Matikas A; Bjöhle J; Barnekow E; Isakssonfriman E; Zouzos A; Tzoras E; Johansson H; Margolin S; Acs B; Boyaci C; Sun W; Zerdes I; Kessler LE; Grybäck P; Hellström M; Hartman J; Brandberg Y; Bergh J; Hatschek T; Foukakis T
• Conference publication: ESMO OPEN. 2024;9:103075

  69P Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides

  Tsiknakis N; Salgkamis D; Tzoras E; Wang K; Liu X; Manikis G; Sifakis EG; Bergh J; Marias K; Zerdes I; Matikas A; Foukakis T
• Journal article: ESMO OPEN. 2024;9:103074

  68P Application of a machine learning model for identifying an ultra-low risk group of early breast cancer patients

  Sarafidis M; Sifakis EG; Bergh J; Foukakis T; Matikas A
• Journal article: ESMO OPEN. 2024;9:103131

  144P Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: A population-based study

  Boman CE; Tranchell C; Liu X; Bergman LE; Toli MA; Bergh J; Foukakis T; Matikas A
• Journal article: ESMO OPEN. 2024;9:103124

  137P Adherence to and optimization of guidelines for risk of recurrence/Prosigna testing using a machine learning model: A Swedish multicenter study

  Kjällquist U; Tsiknakis N; Acs B; Margolin S; Ekholm M; Kessler LE; Lundgren C; Garcia SG; Olsson EJ; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
• Journal article: ESMO OPEN. 2024;9:103099

  111MO Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial

  Foukakis T; Matikas A; Möbus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstrom P; Johansson H; Hellström M; Brandberg Y; Gnant MI; Loibl S; Bergh J
• Journal article: ESMO OPEN. 2024;9:103116

  129P Adherence to adjuvant endocrine therapy in the era of combination treatments: A population-based study

  Bergman LE; Matikas A; Liu X; Foukakis T
• Conference publication: ESMO OPEN. 2024;9:103063

  56P Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial

  Zerdes I; Wang K; Salgkamis D; Zhu Y; Sifakis EG; Acs B; Hartman J; Hatschek T; Bergh J; Matikas A; Foukakis T
• Journal article: CANCER RESEARCH. 2024;84(9):po1-02-14-po1-02-14

  Breast cancer in older women - long-term prognosis by age and subtype in a large population-based cohort

  Chiorescu A; Johansson ALV; Valachis A; Matikas A; Frisell J; Holmberg L; Fredriksson I
• Journal article: CANCER RESEARCH. 2024;84(9):gs02-13-gs02-13

  Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

  Lambertini M; Blondeaux E; Agostinetto E; Hamy-Petit A-S; Kim HJ; Chiodi C; Bernstein-Molho R; Hilbers F; Pogoda K; Lopez EC; Punie K; Bajpai J; Ignatiadis M; Moore H; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong S; Vernieri C; Ruddy K; Dieci MV; Matikas A; Rozenblit M; Garza CV; De Marchis L; Del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; De Giorgi U; Sonnenblick A; Azim H; Partridge A
• Meeting abstract: CANCER RESEARCH. 2024;84(9):po2-07-06-po2-07-06

  Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial

  Wang K; Zhu Y; Zerdes I; Sifakis E; Manikis G; Salgkamis D; Tsiknakis N; Harbers L; Crosetto N; Bergh J; Matikas A; Hatschek T; Foukakis T
• Article: EUROPEAN JOURNAL OF CANCER. 2024;202:114010

  Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

  Helgadottir H; Matikas A; Fernebro J; Frodin J-E; Ekman S; Rodriguez-Wallberg KA
• Editorial: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2024;103(4):775-778

  Breast cancer during pregnancy-The oncologist's point of view

  Matikas A; Bergh J
• Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308

  The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

  Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
• Preprint: RESEARCH SQUARE. 2024

  Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study

  Kjällquist U; Tsiknakis N; Acs B; Margolin S; Kessler LE; Levy S; Ekholm M; Lundgren C; Olsson E; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
• Article: BREAST CANCER RESEARCH. 2024;26(1):38

  Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients

  Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindstroem LS; Tobin NP
• Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2024;200:113830

  Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer

  Foukakis T; Wang K; Zerdes I; Zhu Y; Sifakis E; Tsiknakis N; Manikis G; Salgkamis D; Harbers L; Bergh J; Johansson H; Crosetto N; Lehtio J; Matikas A; Hatschek T
• Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(1):79-87

  Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study

  Digkas E; Smith DR; Wennstig A-K; Matikas A; Tegnelius E; Valachis A
• Review: ONCOLOGIST. 2024;29(1):1-7

  Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

  Villacampa G; Papakonstantinou A; Fredriksson I; Matikas A
• Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2024;331(1):49-59

  Pregnancy After Breast Cancer in Young BRCA Carriers

  Lambertini M; Blondeaux E; Agostinetto E; Hamy A-S; Kim HJ; Di Meglio A; Molho RB; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; De Giorgi U; Sonnenblick A; Chiodi C; Lee Y-J; Maria C; Azim HAJ; Boni L; Partridge AH
• Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023;192:104189

  The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review

  Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
• Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s307-s308

  Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up

  Zerdes I; Matikas A; Mezheyeuski A; Acs B; Johansson H; Manikis G; Boyaci C; Boman CE; Poncet C; Ignatiadis M; Bai Y; Rimm D; MacGrogan G; Cameron DA; Bergh J; Bonnefoi H; Foukakis T
• Editorial: ESMO OPEN. 2023;8(5):101625

  Young oncologists' perspective on the role and future of the clinician-scientist in oncology

  Lim KHJ; Westphalen CB; Berghoff AS; Cardone C; Connolly EA; Guven DC; Kfoury M; Kocakavuk E; Mando P; Mariamidze E; Matikas A; Moutafi M; Oing C; Pihlak R; Punie K; Sanchez-Bayona R; Sobczuk P; Starzer AM; Vuger AT; Zhu H; Cruz-Ordinario MVB; Altuna SC; Canario R; Vuylsteke P; Banerjee S; de Azambuja E; Cervantes A; Lambertini M; Mateo J; Amaral T
• Review: EUROPEAN JOURNAL OF CANCER. 2023;190:112885

  Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis

  Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
• Preprint: RESEARCH SQUARE. 2023

  Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study

  Digkas E; Smith D; Wennstig A-K; Matikas A; Tegnelius E; Valachis A
• Editorial: MOLECULAR ONCOLOGY. 2023;17(4):545-547

  The interplay between eosinophils and T cells in breast cancer immunotherapy

  Zerdes I; Matikas A; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023

  Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02

  Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial

  Zerdes I; Salgkamis D; Matikas A; Selander L; Wang K; Tzoras E; Sifakis E; Agartz S; Chen X; Hellstrom M; Hartman J; Bergh J; Foukakis T; Hatschek T
• Meeting abstract: CANCER RESEARCH. 2023;83(5):p5-02-20-p5-02-20

  Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial

  Wang K; Zhu Y; Zerdes I; Matikas A; Sifakis E; Salgkamis D; Bjohle J; Elinder E; Margolin S; Campos AB; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Johansson H; Hellstrom M; Azavedo E; Hartman J; Bergh J; Hatschek T; Foukakis T
• Preprint: MEDRXIV. 2023

  Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients

  Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström L; Tobin N
• Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540

  Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

  Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
• Book chapter: INTRODUCTION TO ARTIFICIAL INTELLIGENCE: IMAGING INFORMATICS FOR HEALTHCARE PROFESSIONALS. 2023;p. 13-37

  Using Commercial and Open-Source Tools for Artificial Intelligence: A Case Demonstration on a Complete Radiomics Pipeline

  Stamoulou E; Spanakis C; Nikiforaki K; Karantanas AH; Tsiknakis N; Matikas A; Foukakis T; Manikis GC
• Book chapter: BREAST CANCER MANAGEMENT FOR SURGEONS. 2023;p. 203-218

  Principles of Primary Systemic Therapy

  Foukakis T; Matikas A; Valachis A
• Article: ONCOLOGY RESEARCH AND TREATMENT. 2023;46(3):67-71

  Career and Professional Development for Young Oncologists

  Mair MJ; Cardone C; Connolly L; Kfoury M; Lambertini M; Lim J; Mariamidze E; Matikas A; Pihlak R; Punie K; Oing C; Sanchez-Bayona R; Sobczuk P; Zhu H; Berghoff AS; Amaral T
• Review: FRONTIERS IN ONCOLOGY. 2022;12:999843

  Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis

  Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
• Conference publication: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2022;18:233-234

  Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49

  Schmid P; Sohn JH; Jerez Gilarranz Y; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Korbenfeld E; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Hirshfield K; Tryfonidis K; Rugo HS
• Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S604

  Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+breast cancer. A systematic review and network meta-analysis (NMA)

  Villacampa Javierre G; Pascual T; Matikas A; Papakonstantinou A
• Journal article: ANNALS OF ONCOLOGY. 2022;33:s604-s605

  143P Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+ breast cancer. A systematic review and network meta-analysis (NMA)

  Javierre GV; Pascual T; Matikas A; Papakonstantinou A
• Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56

  Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study

  Boman C; Kessler LE; Bergh J; Matikas A; Foukakis T
• Article: BREAST CARE. 2022;17(3):264-271

  Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period

  Matikas A; Kotsakis A; Perraki M; Hatzidaki D; Kalbakis K; Kontopodis E; Nikolaou M; Georgoulias V
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12598

  Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.

  Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12620

  Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.

  Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):593

  Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

  Matikas A; Johansson H; Grybäck P; Bjöhle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

  Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.

  Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

  Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.

  Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

  Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

  Matikas A; Johansson H; Gryback P; Bjohle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

  KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

  Rugo HS; Sohn J; Jerez Gilarranz Y; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Pablo Korbenfeld E; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Baccan C; Tryfonidis K; Schmid P
• Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):tps1118

  KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.

  Rugo HS; Sohn J; Gilarranz YJ; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Korbenfeld EP; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Baccan C; Tryfonidis K; Schmid P
• Letter: BRITISH JOURNAL OF CANCER. 2022;126(11):1661-1662

  Response to A. Chauhan and A. Pal

  Matikas A; Georgoulias V
• Article: BRITISH JOURNAL OF CANCER. 2022;126(11):1563-1569

  Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer

  Matikas A; Kotsakis A; Apostolaki S; Politaki H; Perraki M; Kalbakis K; Nikolaou M; Economopoulou P; Hatzidaki D; Georgoulias V
• Article: CANCERS. 2022;14(11):2615

  Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study

  Kjallquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Hernandez SG; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
• Meeting abstract: ANNALS OF ONCOLOGY. 2022;33:S125

  Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer

  Wang K; Zerdes I; Sifakis EG; Johansson HJ; Mezheyeuski A; Lehtio J; Bergh J; Hatschek T; Matikas A; Foukakis T
• Review: CANCERS. 2022;14(8):1999

  Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution

  Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
• Article: JOURNAL OF INFECTIOUS DISEASES. 2022;225(7):1151-1161

  Regular Use of Depot Medroxyprogesterone Acetate Causes Thinning of the Superficial Lining and Apical Distribution of Human Immunodeficiency Virus Target Cells in the Human Ectocervix

  Edfeldt G; Lajoie J; Rohl M; Oyugi J; Ahlberg A; Khalilzadeh-Binicy B; Bradley F; Mack M; Kimani J; Omollo K; Wahlby C; Fowke KR; Broliden K; Tjernlund A
• Journal article: CANCER RESEARCH. 2022;82(4):p3-18-03-p3-18-03

  Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)

  Wang K; Duinmeijer A; Matikas A; Altena R; Johansson H; Fredholm H; Foukakis T
• Editorial: ANNALS OF ONCOLOGY. 2021;32(12):1457-1459

  Adjuvant abemaciclib for high-risk breast cancer: the story continues

  Spring L; Matikas A; Bardia A; Foukakis T
• Article: NPJ BREAST CANCER. 2021;7(1):144

  Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study

  Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
• Article: CANCERS. 2021;13(18):4655

  Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer

  Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
• Review: CANCER TREATMENT REVIEWS. 2021;99:102257

  Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

  Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
• Editorial: BREAST CARE. 2021;16(4):422-428

  Expert Discussion: HER2-Positive Breast Cancer

  Foukakis T; Matikas A; Oikonomidou O; Andreopoulou E; Mavroudis D
• Conference publication: ANNALS OF ONCOLOGY. 2021;32:S70-S71

  Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study

  Boman CE; Kessler LE; Bergh J; Matikas A; Foukakis T
• Article: ESMO OPEN. 2021;6(2):100076

  bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

  Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
• Conference publication: CANCER RESEARCH. 2021;81(4_Supplement):ps18-27-ps18-27

  Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial

  Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
• Editorial: ANNALS OF ONCOLOGY. 2021;32(2):129-132

  SOLAR1s: alpelisib returns to earth?

  Matikas A; Foukakis T
• Editorial: ESMO OPEN. 2021;6(1):100017

  ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer

  Punie K; Matikas A
• Conference publication: CANCER RESEARCH. 2021;81(4)

  Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial

  Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
• Editorial: ESMO OPEN. 2021;6(1):100014

  ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer

  Matikas A; Lambertini M
• Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387

  Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience

  Kessler LE; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
• Article: ESMO OPEN. 2020;5(6):e001032

  PD-1 protein and gene expression as prognostic factors in early breast cancer

  Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
• Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S328

  Heterogeneity of PD-L1 expression at the protein and mRNA levels in early breast cancer

  Zerdes I; Stogiannitsi M; Bergh J; Hatschek T; Foukakis T; Matikas A
• Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1196

  Disparities in access to oncology clinical trials in Europe in the period 2009-2019

  Carneiro A; Amaral TMS; Brandao M; Scheffler M; Bol K; Ferrara R; Jalving M; Lo Russo G; Marquez-Rodas I; Matikas A; Mezquita L; Morgan G; Onesti CE; Pilotto S; Saloustros E; Trapani D
• Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651

  Chemotherapy use near the end-of-life in patients with metastatic breast cancer

  Kessler LE; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):545

  PD-1 protein and gene expression in early breast cancer: Prognostic implications.

  Zerdes I; Matikas A; Lövrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)

  PD-1 protein and gene expression in early breast cancer: Prognostic implications.

  Zerdes I; Matikas A; Lovrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
• Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963

  Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease

  Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
• Article: CANCER. 2020;126(6):1175-1182

  Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial

  Papakonstantinou A; Matikas A; Bengtsson NO; Malmstrom P; Hedayati E; Steger G; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
• Article: ACTA ONCOLOGICA. 2020;59(1):75-81

  Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer

  Papakonstantinou A; Hedayati E; Hellstrom M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
• Journal article: ANNALS OF ONCOLOGY. 2019;30:v86-v87

  258P Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

  Papakonstantinou A; Matikas A; Hellström M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
• Journal article: ANNALS OF ONCOLOGY. 2019;30:v136

  373P Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study

  Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
• Conference publication: ANNALS OF ONCOLOGY. 2019;30:86

  Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

  Papakonstantinou A; Matikas A; Hellstrom M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
• Conference publication: ANNALS OF ONCOLOGY. 2019;30

  Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study

  Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
• Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726

  Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data

  Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
• Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050

  Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

  Matikas A; Foukakis T; Swain S; Bergh J
• Article: TARGETED ONCOLOGY. 2019;14(3):285-293

  MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer

  Matikas A; Souglakos J; Katsaounis P; Kotsakis A; Kouroupakis P; Pantazopoulos N; Kentepozidis N; Nikolaidi A; Messaritakis I; Tzovara I; Hatzidaki D; Prinarakis E; Georgoulias V
• Review: AUTOIMMUNITY REVIEWS. 2019;18(6):615-620

  G-CSF-induced aortitis: Two cases and review of the literature

  Parodis I; Dani L; Notarnicola A; Martenhed G; Fernstrom P; Matikas A; Wiklander OPB
• Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):550

  Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2-early breast cancer.

  Zerdes I; Sifakis EG; Tobin N; Bergh JCS; Matikas A; Foukakis T
• Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e14284

  Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.

  Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh JCS; Valachis A; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):553

  Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

  Foukakis T; Papakonstantinou A; Matikas A; Bengtsson N-O; Malmstrom P; Hedayati E; Steger GG; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Bergh JCS
• Review: CANCERS. 2019;11(5):E628-628

  Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

  Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
• Editorial: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397

  Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology

  Matikas A; Foukakis T; Bergh J
• Meeting abstract: CANCER RESEARCH. 2019;79(4):p2-08-25-p2-08-25

  PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer

  Zerdes I; Sifakis E; Matikas A; Tobin NP; Charlotte R; Rassidakis GZ; Bergh J; Foukakis T
• Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114

  Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

  Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh J
• Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281

  RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis

  Matikas A; Foukakis T; Bergh J
• Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017

  Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

  Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
• Review: ONCOGENE. 2018;37(34):4639-4661

  Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

  Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
• Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):538

  Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.

  Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh JCS
• Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355

  Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

  Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
• Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488

  Immune gene expression and response to chemotherapy in advanced breast cancer

  Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
• Article: MOLECULAR ONCOLOGY. 2018;12(1):21-32

  Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes

  Spiliotaki M; Mavroudis D; Kokotsaki M; Vetsika E-K; Stoupis I; Matikas A; Kallergi G; Georgoulias V; Agelaki S
• Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151

  Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts

  Matikas A; Foukakis T; Bergh J
• Journal article: ANNALS OF ONCOLOGY. 2017;28:v68

  219P Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

  Matikas A; Lövrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
• Conference publication: ANNALS OF ONCOLOGY. 2017;28

  Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

  Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
• Article: TRANSLATIONAL ONCOLOGY. 2017;10(4):693-698

  Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer1

  Matikas A; Voutsina A; Lagoudaki E; Hatzidaki D; Trypaki M; Stoupis G; Tzardi M; Mavroudis D; Georgoulias V
• Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017;114:91-101

  Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine

  Matikas A; Foukakis T; Bergh J
• Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e12036

  Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.

  Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Carlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm BK; Lindman H; Malmstrom P; Villman KK; Foukakis T; Bergh JCS
• Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2017;17(4):319-326

  Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer

  Matikas A; Foukakis T; Michalakis I; Georgoulias V
• Journal article: CANCER RESEARCH. 2017;77:p1-01-12-p1-01-12

  Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

  Agelaki S; Spiliotaki M; Kokotsaki M; Matikas A; Vetsika E-K; Georgoulias V; Mavroudis D
• Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017;110:1-12

  Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity

  Matikas A; Mistriotis D; Georgoulias V; Kotsakis A
• Review: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. 2016;8(12):810-818

  Role of circulating free DNA in colorectal cancer

  Matikas A; Voutsina A; Trypaki M; Georgoulias V
• Review: EXPERT REVIEW OF RESPIRATORY MEDICINE. 2016;10(11):1229-1241

  The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update

  Matikas A; Georgoulias V; Kotsakis A
• Review: CLINICAL LUNG CANCER. 2016;17(6):507-516

  Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges

  Matikas A; Syrigos KN; Agelaki S
• Review: CLINICAL LUNG CANCER. 2016;17(6):474-482

  Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer

  Matikas A; Kentepozidis N; Georgoulias V; Kotsakis A
• Article: ANNALS OF ONCOLOGY. 2016;27(10):1873-1878

  Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

  Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V
• Article: BRITISH JOURNAL OF CANCER. 2016;115(7):784-788

  A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

  Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
• Review: TRANSLATIONAL LUNG CANCER RESEARCH. 2016;5(4):389-400

  Targeting angiogenesis in small cell lung cancer

  Stratigos M; Matikas A; Voutsina A; Mavroudis D; Georgoulias V
• Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2016;78(2):369-376

  Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

  Matikas A; Kentepozidis N; Ardavanis A; Vaslamatzis M; Polyzos A; Emmanouilides C; Katsaounis P; Koinis F; Xynogalos S; Christopoulou A; Ziras N; Tegos T; Prinarakis E; Hatzidaki D; Georgoulias V; Kotsakis A
• Review: EXPERT OPINION ON EMERGING DRUGS. 2016;21(2):157-166

  Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients

  Matikas A; Georgoulias V; Kotsakis A
• Journal article: FORUM OF CLINICAL ONCOLOGY. 2016;7(1):17-27

  Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

  Matikas A; Aggelaki S
• Article: BREAST CANCER RESEARCH. 2015;17(1):113

  Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients

  Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
• Conference publication: CANCER RESEARCH. 2015;75:374

  Expression of the autophagosomal marker LC3 on circulating tumor cells (CTCs) of patients with early and metastatic breast cancer (BC)

  Spiliotaki M; Koukorava C; Matikas A; Georgoulias V; Mavroudis D; Agelaki S
• Review: CLINICAL LUNG CANCER. 2015;16(4):252-261

  Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs

  Matikas A; Mistriotis D; Georgoulias V; Kotsakis A
• Article: BMC CANCER. 2015;15:399

  Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer

  Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
• Review: CANCERS. 2015;7(1):439-449

  The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

  Matikas A; Asimakopoulou N; Georgoulias V; Souglakos J
• Article: CASE REPORTS IN ONCOLOGICAL MEDICINE. 2015;2015:659624-4

  Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI

  Nikolaou C; Matikas A; Papavasilopoulou M; Mavroudis D; Vamvakas L
• Journal article: ARCHIVES OF HELLENIC MEDICINE. 2015;32(1):28-35

  Advances in the treatment of metastatic melanoma

  Matikas A; Mavroudis D
• Review: FUTURE ONCOLOGY. 2015;11(6):997-1009

  Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma

  Matikas A; Mavroudis D
• Journal article: FORUM OF CLINICAL ONCOLOGY. 2014;5(2):20-31

  Triple-Negative Breast Cancer: One Or More Entities?

  Matikas A; Lazaridis G; Agelaki S
• Journal article: JOURNAL OF GERIATRIC ONCOLOGY. 2014;5:s36-s37

  Gemcitabine combined with carboplatin in the first-line of treatment of elderly patients with non-small-cell lung cancer: A multicenter phase II trial by the Hellenic Oncology Research Group (HORG)

  Karampeazis A; Vamvakas L; Kentepozidis N; Agelaki S; Kotsakis A; Polyzos A; Milaki G; Christophyllakis C; Matikas A; Kouroussis C; Mavroudis D; Georgoulias V
• Article: ANTICANCER RESEARCH. 2014;34(9):5111-5115

  Plasmablastic Lymphoma of the Breast in an Immunocompetent Patient: Long-lasting Complete Response Induced by Chemotherapy and Autologous Stem Cell Trasplantation

  Matikas A; Kanellis G; Papadimitriou C; Papadaki T; Kotsakis A; Dimopoulos MA; Georgoulias V
• Article: ANTICANCER RESEARCH. 2014;34(8):4411-4414

  A Case of Herpes Simplex-associated Encephalitis After Brain Irradiation for Lung Cancer Metastases

  Matikas A; Kontopodis E; Nintos G; Bilidas T; Kofteridis DP; Papadaki EZ; Lyraraki E; Kanatsouli K; Mavroudis D
• Article: BMC CANCER. 2014;14:277

  Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged > 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

  Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J
• Article: CHROMATOGRAPHIA. 2014;77(19-20):1275-1281

  Pre-Column Derivatization HPLC Procedure for the Quantitation of Aluminium Chlorohydrate in Antiperspirant Creams Using Quercetin as Chromogenic Reagent

  Kalogria E; Varvaresou A; Papageorgiou S; Protopapa E; Tsaknis I; Matikas A; Panderi I
• Journal article: JOURNAL OF GERIATRIC ONCOLOGY. 2013;4:s40-s41

  A retrospective analysis regarding the parameters, which influence the administration of adjuvant chemotherapy in for elderly patients (>70years) with stage II or III colon cancer in the daily clinical practice

  Asimakopoulou N; Papakonstantinou P; Souglakos J; Karampeazis A; Saridaki Z; Koinis P; Matikas A; Nikolaou C; Georgoulias V; Vamvakas L
• Article: BMJ CASE REPORTS. 2013;2013:bcr2013200502

  A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.

  Matikas A; Vardakis N; Souglakos J; Georgoulias V
• Article: BMJ CASE REPORTS. 2013;2013:bcr2013008834

  A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation.

  Matikas A; Tzannou I; Oikonomopoulou D; Bakiri M
• Article: BMJ CASE REPORTS. 2013;2013:bcr2012008311

  Primary abdominal muscle lymphoma.

  Matikas A; Oikonomopoulou D; Tzannou I; Bakiri M
• Article: ACTA HAEMATOLOGICA. 2013;130(4):291-296

  Primary Bone Lymphoma: A Retrospective Analysis of 22 Patients Treated in a Single Tertiary Center

  Matikas A; Briasoulis A; Tzannou I; Oikonomopoulou D; Bakiri M; Karmiris T; Harhalakis N
• Visa fler

Finansiering

Medarbetare och kontakt

Gruppledare

• 

  Alexios Matikas

  Anknuten till Forskning | Docent

  E-postadress alexios.matikas@ki.se

Alla medarbetare i gruppen

• Caroline Boman

  Doktorand

  E-postadress caroline.boman@ki.se
• Behnaz Binicy

  Anknuten till Forskning

  E-postadress behnaz.khalilzadehbinicy@ki.se
• Xingrong Liu

  Statistiker

  E-postadress xingrong.liu@ki.se
• 

  Dimitrios Salgkamis

  Klinisk Assistent

  E-postadress dimitrios.salgkamis@ki.se
• 

  Michail Sarafidis

  Postdoktor

  E-postadress michail.sarafidis@ki.se